Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Evidence for EMF-Cancer Link Deemed Weak, Risk Small

August 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

RESEARCH TRIANGLE PARK, NC-After 6 years of research and 2 years of review, the National Institute of Environmental Health Sciences reported to Congress that the evidence that low-frequency electromagnetic fields (EMFs) can cause cancer and other human diseases is weak, but added that EMF exposure “cannot be recognized as entirely safe.”

RESEARCH TRIANGLE PARK, NC—After 6 years of research and 2 years of review, the National Institute of Environmental Health Sciences reported to Congress that the evidence that low-frequency electromagnetic fields (EMFs) can cause cancer and other human diseases is weak, but added that EMF exposure “cannot be recognized as entirely safe.”

A 1996 report by the Institute of Medicine found scant evidence to support EMF as a cancer risk, and federal investigators recently discredited a study from the Energy Department’s Lawrence Berkeley Laboratory because a scientist omitted data that did not support a link between EMFs and cancer.

Articles in this issue

False positives frequent in CT lung cancer screening trial
Stereotactic Core Biopsy Establishes Many Prognostic Factors
Breast Cancer Prevention With Tamoxifen Appears Cost-Effective
NCI Discovers Gene Variations From Existing Databases
CPDR Unveils First Center Solely for Prostate Cancer Research
Going Beyond CHOP in Advanced Large-Cell Lymphoma
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion
Ernst Wynder, Pioneer in Preventive Medicine
AHCPR Plans Health Care Market, Managed Care Research Centers
NSAIDs May Protect Against Common GI Cancers
Four Researchers Receive General Motors Awards
Anal Condylomata More Threatening in HIV+ Patients
IOM Finds No Link Between Silicone Implants and Cancer
IL-12 Gene Therapy Inhibits Osteosarcoma Lung Mets in Mice
Law May Play an Important Role in End of Life Decisions
Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content
Advertisement

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC

Russ Conroy
October 12th 2025
Article

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Serplulimab plus chemotherapy also achieved a threefold higher pathological complete response rate and a significant reduction in the risk of recurrence compared with the control arm.

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

Tim Cortese
October 10th 2025
Article

An independent data monitoring committee suggested the submission of an early NDA for serplulimab plus chemotherapy in early-stage gastric cancer.


A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.


A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor-positive GEP-NETs.

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

Roman Fabbricatore
October 10th 2025
Article

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.


Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

OST-HER2 Exhibits Survival Benefit in Pulmonary Metastatic Osteosarcoma

Roman Fabbricatore
October 10th 2025
Article

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

Related Content
Advertisement

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC

Russ Conroy
October 12th 2025
Article

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Serplulimab plus chemotherapy also achieved a threefold higher pathological complete response rate and a significant reduction in the risk of recurrence compared with the control arm.

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

Tim Cortese
October 10th 2025
Article

An independent data monitoring committee suggested the submission of an early NDA for serplulimab plus chemotherapy in early-stage gastric cancer.


A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP
October 6th 2025
Podcast

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.


A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor-positive GEP-NETs.

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

Roman Fabbricatore
October 10th 2025
Article

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.


Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

OST-HER2 Exhibits Survival Benefit in Pulmonary Metastatic Osteosarcoma

Roman Fabbricatore
October 10th 2025
Article

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.